Analyst Mani Foroohar of Leerink Partners maintained a Buy rating on RegenXBio (RGNX – Research Report), boosting the price target to $38.00. Don't Miss our Black Friday Offers: Discover the latest ...
Fintel on MSN4d
Leerink Partners Downgrades 908 Devices (MASS)Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...
(Bloomberg) -- Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from ...
Fintel on MSN6d
Leerink Partners Upgrades Bristol-Myers Squibb (BMY)Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...
Research analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Ardent Health Partners in a ...
Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...
Industry Veterans Grant Curry and Jason Truman Join Leerink Partners. BOSTON, Nov. 14, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, announced today ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...
Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (WBAG:BMYS) from Market Perform to Outperform. There are 3,419 funds or institutions ...
On Friday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.8 which represents a decrease of $-0.22 or -3.13% from the prior close of $7.02. The stock opened at $7.05 and touched a low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback